The increasing complexity of modern protein therapeutics and the demand for faster development of new therapeutics require not only advanced analytical tools that provide in-depth understanding of the product quality attributes (PQAs) that are crucial for safety and efficacy but also the implementation of a control strategy to ensure that the released drug product meets the desired quality profile. The multi-attribute method (MAM), a liquid chromatography–mass spectrometry (LC-MS) approach, has emerged as a transformative solution that provides site-specific monitoring of multiple critical quality attributes (CQAs) in a single workflow, replacing several conventional profile-based assays. The MAM achieves comprehensive quality oversight through two primary mechanisms: targeted attribute quantitation (TAQ) for the simultaneous quantification of predefined known modifications, and new peak detection (NPD) for identifying unforeseen impurities, thereby establishing a robust, “double-layered” control strategy. This article reviews the practical challenges and current industry practices for successfully implementing the MAM within current good manufacturing practice (cGMP) environments. The successful transition of the MAM from a specialized characterization tool to a validated quality control (QC) cornerstone relies on a framework built upon four foundational pillars: stringent instrument qualification paired with compliance-ready informatics, proactive and strictly scheduled instrument maintenance, rigorous system suitability testing (SST), and phase-appropriate method validation and transfer. The challenges of global method transfer and the solutions to mitigate inter-laboratory variability are discussed. Finally, the review explores the emerging trends shaping the future of the MAM in QC and the critical role of the MAM in facilitating real-time release testing (RTRT) in next-generation autonomous manufacturing.
Background/Objectives: The Multi-Attribute Method (MAM) uses LC-MS peptide mapping for targeted attribute quantitation (TAQ) and untargeted New Peak Detection (NPD) in product quality monitoring and quality control of biotherapeutics. As automated liquid handling systems are adopted, data demonstrating similar performance for both TAQ and NPD are essential to implement an automatic sample preparation workflow to fully achieve MAM capabilities. This study compares manual versus automated sample preparation workflows for both TAQ and NPD. Methods: Peptide mapping sample preparation was performed manually and on an automated liquid handling system. TAQ was evaluated using a reference monoclonal antibody (mAb1) while NPD was assessed by spiking a second monoclonal antibody (mAb2) into mAb1 (0.5–2% w/w relative abundance). NPD specificity and sensitivity were qualified using a product-specific peptide library, multiple bracketing comparisons, and a statistically derived Fold Change Detection (FCD) threshold. Results: For TAQ, the automated workflow demonstrated comparable performance to the manual method, with minimal quantitative differences and high reproducibility across 28 monitored product quality attributes. For NPD, all expected mAb2 peptides were detected with no false positives at each spike level. No new peaks were observed when comparing bracketing unspiked mAb1 samples, confirming specificity for NPD. Conclusions: The results demonstrate that automated sample preparation yields consistent TAQ and NPD data compared to manual methods and can be used for routine product quality monitoring.